These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 9932717

  • 1. Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs. dopamine and noradrenaline.
    Millan MJ, Gobert A, Girardon S, Dekeyne A.
    Eur J Pharmacol; 1999 Jan 08; 364(2-3):147-50. PubMed ID: 9932717
    [Abstract] [Full Text] [Related]

  • 2. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats.
    Kitaichi Y, Inoue T, Nakagawa S, Boku S, Kakuta A, Izumi T, Koyama T.
    Eur J Pharmacol; 2010 Nov 25; 647(1-3):90-6. PubMed ID: 20816814
    [Abstract] [Full Text] [Related]

  • 3. Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats.
    Dekeyne A, Gobert A, Iob L, Cistarelli L, Melon C, Millan MJ.
    Psychopharmacology (Berl); 2001 Nov 25; 158(2):213-8. PubMed ID: 11702096
    [Abstract] [Full Text] [Related]

  • 4. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.
    Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F.
    Eur J Neurosci; 2000 Mar 25; 12(3):1079-95. PubMed ID: 10762339
    [Abstract] [Full Text] [Related]

  • 5. Differential effects of adjunctive methylphenidate and citalopram on extracellular levels of serotonin, noradrenaline and dopamine in the rat brain.
    Weikop P, Yoshitake T, Kehr J.
    Eur Neuropsychopharmacol; 2007 Oct 25; 17(10):658-71. PubMed ID: 17383162
    [Abstract] [Full Text] [Related]

  • 6. Fluoxetine increases extracellular dopamine in the prefrontal cortex by a mechanism not dependent on serotonin: a comparison with citalopram.
    Pozzi L, Invernizzi R, Garavaglia C, Samanin R.
    J Neurochem; 1999 Sep 25; 73(3):1051-7. PubMed ID: 10461894
    [Abstract] [Full Text] [Related]

  • 7. The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram.
    Arborelius L, Nomikos GG, Hertel P, Salmi P, Grillner P, Höök BB, Hacksell U, Svensson TH.
    Naunyn Schmiedebergs Arch Pharmacol; 1996 May 25; 353(6):630-40. PubMed ID: 8738296
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: a neurochemical, electrophysiological, and behavioral characterization.
    Gobert A, Brocco M, Dekeyne A, Di Cara B, Bouchez G, Lejeune F, Gannon RL, Millan MJ.
    Neuropsychopharmacology; 2009 Mar 25; 34(4):1039-56. PubMed ID: 18830239
    [Abstract] [Full Text] [Related]

  • 10. Effect of paroxetine on extracellular serotonin and dopamine levels in the prefrontal cortex.
    Nakayama K.
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb 25; 365(2):102-5. PubMed ID: 11819027
    [Abstract] [Full Text] [Related]

  • 11. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain.
    Hertel P, Nomikos GG, Iurlo M, Svensson TH.
    Psychopharmacology (Berl); 1996 Mar 25; 124(1-2):74-86. PubMed ID: 8935802
    [Abstract] [Full Text] [Related]

  • 12. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
    Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, Middlemiss DN, Dawson LA.
    Eur J Pharmacol; 2005 Mar 07; 510(1-2):49-57. PubMed ID: 15740724
    [Abstract] [Full Text] [Related]

  • 13. Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors.
    Weikop P, Kehr J, Scheel-Krüger J.
    J Psychopharmacol; 2007 Nov 07; 21(8):795-804. PubMed ID: 17984160
    [Abstract] [Full Text] [Related]

  • 14. Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats.
    Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ.
    J Neurochem; 1997 Dec 07; 69(6):2616-9. PubMed ID: 9375697
    [Abstract] [Full Text] [Related]

  • 15. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex.
    Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, Wong DT, Perry KW.
    Psychopharmacology (Berl); 2002 Apr 07; 160(4):353-61. PubMed ID: 11919662
    [Abstract] [Full Text] [Related]

  • 16. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.
    Felton TM, Kang TB, Hjorth S, Auerbach SB.
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar 07; 367(3):297-305. PubMed ID: 12644903
    [Abstract] [Full Text] [Related]

  • 17. Differential effect of local infusion of serotonin reuptake inhibitors in the raphe versus forebrain and the role of depolarization-induced release in increased extracellular serotonin.
    Tao R, Ma Z, Auerbach SB.
    J Pharmacol Exp Ther; 2000 Aug 07; 294(2):571-9. PubMed ID: 10900234
    [Abstract] [Full Text] [Related]

  • 18. Serotonin-2C antagonism augments the effect of citalopram on serotonin and dopamine levels in the ventral tegmental area and nucleus accumbens.
    Visser AK, Kleijn J, van Faassen MH, Dremencov E, Flik G, Kema IP, Den Boer JA, van Waarde A, Dierckx RA, Bosker FJ.
    Neurochem Int; 2015 Feb 07; 81():10-5. PubMed ID: 25542858
    [Abstract] [Full Text] [Related]

  • 19. Combination of escitalopram and a 5-HT(₁A) receptor antagonist selectively decreases the extracellular levels of dopamine in the nucleus accumbens relative to striatum through 5-HT(₂C) receptor stimulation; suggestive of antipsychotic potential.
    Hovelsø N, Sager TN, Mørk A.
    Pharmacol Biochem Behav; 2011 Jan 07; 97(3):479-85. PubMed ID: 20937301
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.